Search For
/
Stocks
Intraday Booster
Sector Booster
Stock Screener
Market Pulse
Screeners
More
Go Prime
My Plans
Privacy Policy
Contact
Refer & EarnScreenersMain
Stock Screener
Create Screener
Explore Screeners
Community ScreenersTrading Screeners
CandleSticks Screener
Top Gainers & Losers
Opening Range Breakout
Stock Screener AI
Stock Quality Scorecard
Overvalued StocksNewUndervalued StocksNewTechnical Screeners
NR4 Stocks
NR7 Stocks
Previous Day High Breakout
Previous Day Low Breakout
Previous Day Open Breakout
Bullish Crossover Stocks
Bearish Crossover Stocks
High Volume Shocker
VWAP Breakout Stocks
Range High Breakout
Range Low BreakoutMoreMarkets
Global Market Today
Global Indices
Indian Indices
NIfty TodayPrecious Metals
Gold Price TodayNew
Silver Price TodayNew
Platinum Price TodayNewSmart Money
FII DII DataNew
FII Buying
NSE Insider Trading
SLB Stocks DataDerivatives
FnO Movements
NSE F&O Lot Size
Ban ListAnalysis & Calendars
Technical DashboardSector Booster
Sector AnalysisNew
Result Calendar
Economic Calendar
Price Chart
Compare with Peers
Historical Ratios
Track top 12 most important financial ratios
P/E Ratio: Price to Earnings - Most used valuation metric
Loading chart...
Analyzing Investment Quality
Processing 9 key metrics...
Key Metrics
Hover for details
Valuation
Market Cap
₹2,851.6 Cr
Market Cap
Total market value of companyP/E Ratio
-
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)P/B Ratio
4.13
P/B Ratio
Price to Book Value. <3 may indicate undervaluationEPS
₹-1.58
EPS
Earnings Per Share. Higher and growing is positiveProfitability
ROE
-1.69%
ROE
Return on Equity. >15% is good, >20% is excellentROCE
11.00%
ROCE
Return on Capital Employed. >15% is goodNet Margin
-1.66%
Net Margin
Net profit as % of revenue. >10% is goodOperating Margin
-%
Operating Margin
Operating profit margin. >15% is goodGrowth
EPS Growth (5Y)
-%
EPS Growth (5Y)
5-year EPS growth. >15% is strongRevenue Growth (5Y)
9.70%
Revenue Growth (5Y)
5-year revenue growth. >10% is goodQtr Sales Growth
11.20%
Qtr Sales Growth
Quarter-over-quarter sales growthQtr Profit Growth
77.80%
Qtr Profit Growth
Quarter-over-quarter profit growthFinancial Health
Debt/Equity
0.76
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellentBook Value
₹47.98
Book Value
Net asset value per shareDividend Yield
0.90%
Dividend Yield
Annual dividend as % of price. >2% is goodPromoter Holding
49.10%
Promoter Holding
Promoter stake. >50% shows confidenceGood
Average
Needs Attention
SWOT Analysis
Strengths
2 points- •Promoter holding in Camlin Fine Sciences has substantially increased from 17.65% in June 2022 to 49.09% in March 2025, signifying heightened confidence in the company's future and potentially mitigating public shareholding risks.
- •Despite recent quarterly losses, Camlin Fine Sciences shows positive quarterly sales growth, with an 11.2% rise in the latest quarter, suggesting potential for future profitability improvements and operational efficiency gains.
Weaknesses
6 points- •Camlin Fine Sciences' Return on Equity (ROE) stands at a negative -15%, indicating insufficient returns on shareholder investments. This is a major concern for potential investors and highlights operational inefficiencies.
- •The company carries a high debt-to-equity ratio of 0.76, implying substantial reliance on debt financing. This elevates financial risk and makes the company vulnerable to economic downturns and interest rate hikes.
Opportunities
2 points- •Camlin Fine Sciences operates within the Specialty Chemicals sector, a dynamic and expanding industry with significant potential for high returns. This positions the company favorably for future growth within a robust market.
- •The company's positive quarterly sales growth, despite recent losses, presents an opportunity to improve profitability through operational efficiency enhancements and strategic cost-cutting measures.
Threats
3 points- •Camlin Fine Sciences faces intense competition from established peers like Pidilite Inds. and Atul, who often exhibit stronger profitability and lower PE ratios, potentially limiting market share and pricing power.
- •Given its high debt-to-equity ratio of 0.76 and negative profitability, Camlin Fine Sciences is highly vulnerable to economic downturns or rising interest rates, which could further strain its financial health.
Segment-wise Financial Analysis
Fetching Financials...
Fetching Balance Sheet...
Fetching Cash Flow...
Shareholding Pattern
Loading shareholding data...
Company Insider Trading Activity
No insider trading data available
Corporate Action
Company Announcements
Technical Analysis & Indicators
Standard pivot points - most widely used
Pivot Points (CLASSIC)
| Level | Price | Distance | % Change |
|---|---|---|---|
| R4 | ₹118.17 | +₹15.21 | +14.77% |
| R3 | ₹111.77 | +₹8.81 | +8.56% |
| R2 | ₹107.78 | +₹4.82 | +4.68% |
| R1 | ₹105.37 | +₹2.41 | +2.34% |
| PIVOT | ₹101.38 | -1.58 | -1.53% |
| CURRENT | ₹102.96 | - | - |
| S1 | ₹86.17 | -₹16.79 | -16.31% |
| S2 | ₹92.57 | -₹10.39 | -10.09% |
| S3 | ₹94.98 | -₹7.98 | -7.75% |
| S4 | ₹98.97 | -₹3.99 | -3.88% |
CPR Levels
Support
Resistance
S4
N/A
S3
N/A
S2
N/A
S1
N/A
| CPR |
BC: N/AP: N/ATC: N/A
R1
N/A
R2
N/A
R3
N/A
R4
N/A
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment
is trading CPR, indicating
● CPR Width
CPR is
● Opening Range
Day's range: ~
● Price Position
Trading Inside opening range
Delivery Volume Analysis & Trading Activity
Latest Volume+14.4% vs avg
6.70L
(02 Apr 2026)Delivery %-16.4% vs avg
36.5%
(02 Apr 2026)Avg Volume (20D)20-day average
5.86L
(04 Mar - 02 Apr)Avg Delivery %Trend ↓
52.9%
(04 Mar - 02 Apr)Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.
Peer Comparison & Industry Benchmarking
Quick Compare
Largest by Market Cap
Asian Paints Ltd
2.34L ₹ Cr
Best Profit Growth
Jubilant Agri & Consumer Products Ltd
69.30 %
Highest Dividend Yield
Advanced Enzyme Technologies Ltd
1.75 %
Peer Comparison
| Company Name |
|---|
 Advanced Enzyme Technologies Ltd |
 Asian Paints Ltd |
 Balaji Amines Ltd |
 Fineotex Chemical Ltd |
 Foseco India Ltd |
 Jubilant Agri & Consumer Products Ltd |
 Kiri Industries Ltd |
 Neogen Chemicals Ltd |
 Rossari Biotech Ltd |
 Raghav Productivity Enhancers Ltd |
 S H Kelkar & Company Ltd |
 Tatva Chintan Pharma Chem Ltd |
 XPRO India Ltd |
About
Camlin Fine Sciences Ltd
Camlin Fine Sciences Limited (CFSL) is a prominent player in the specialty chemicals industry, operating both domestically within India and on a global scale. The company's core business revolves around the research, development, manufacturing, and marketing of a diverse range of specialty chemicals, ingredients, and additive blends. Their offerings cater to a wide array of sectors, highlighting the versatility and broad applicability of their product portfolio.
A significant portion of CFSL's business focuses on providing shelf-life enhancement solutions for various industries. This includes a comprehensive selection of antioxidants (like Butylated Hydroxy Toluene and Ascorbyl palmitate), emulsifiers, mold inhibitors, antibacterial agents, and other preservatives. They also offer a compelling line of plant-based antioxidants, such as mixed tocopherols, green tea extract, and rosemary extract, marketed under their Xtendra and NaSure brands. These solutions are particularly valuable in extending the usability and quality of products across multiple sectors.
Beyond shelf-life solutions, CFSL also manufactures and distributes aroma ingredients, such as vanillin and ethyl vanillin, which are critical components in the fragrance and flavor industries. Furthermore, they delve into the health and wellness sector with dedicated products and offer performance chemicals like hydroquinone and catechol, demonstrating a commitment to diverse market segments and applications.
The company's clientele spans a broad spectrum of industries, including food and beverage, pet food, animal nutrition, rendering, health and wellbeing, general chemicals, biofuel, and aroma technical applications. This diversified customer base underscores the widespread demand for CFSL's high-quality specialty chemicals and contributes to the company's robust market position. Established in 1931 and headquartered in Mumbai, India, Camlin Fine Sciences Limited has a long history of innovation and adaptation within the ever-evolving chemical industry.
COMPANY FACTS - CAMLINFINE
Registered Address
2nd floor, In G.S. Point, CST Road,, Kalina, Santacruz (East)
Mumbai
MAHARASHTRA
IN
Company Details
Group: Materials
Sector: Materials
Industry: Chemicals
Exchange: NATIONAL STOCK EXCHANGE OF INDIA
Employees: 624
IPO Date: 20/01/2015
MANAGEMENT - CAMLINFINE
Mr. Ashish Dandekar
Chairman of the Board, Managing Director
Mr. Santosh Parab
Chief Financial Officer
Mr. Nilesh Jadhav
Chief Operating Officer
Mr. Rahul Sawale
Chief Compliance Officer, Vice President - Legal, Company Secretary
Mr. Nirmal Momaya
Managing Director
Mr. Arjun Dukane
Executive Director - Technical
Ms. Anagha Dandekar
Non-Executive Non-Independent Director
Mr. Jens Nieuwenborgh
Non-Executive Non-Independent Director
Mr. Harsha Raghavan
Non-Executive Non-Independent Director
Mr. Joseph Dsouza
Non-Executive Independent Director
Ms. Radhika Dudhat
Additional Non-Executive Independent Director
Mr. Abeezar Faizullabhoy
Additional Non-Executive Independent Director
Investor Questions Answered
Camlin Fine Sciences Ltd (CAMLINFINE) Stock FAQs
Get answers to the most common questions about Camlin Fine Sciences Ltd stock price, fundamentals, financial metrics, and investment analysis
The current share price of Camlin Fine Sciences Ltd (CAMLINFINE) is ₹102.96. Today, the stock has gained by ₹1.40 (1.38%), trading in a range of ₹97.39 to ₹103.79. The stock opened at ₹101 with a trading volume of 6,70,358 shares.
Camlin Fine Sciences Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹2,851.6 crores, P/E ratio of 0.00, ROE of -1.69%, and ROCE of 11.00%. The dividend yield stands at 0.90%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Camlin Fine Sciences Ltd (CAMLINFINE) is ₹333.3, while the 52-week low is ₹96.21. Currently trading at ₹102.96, the stock is 2.8% away from its 52-week low and 69.1% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Camlin Fine Sciences Ltd stock at ₹102.96 depends on multiple factors. The stock is currently trading with a P/E ratio of 0.00 and P/B ratio of N/A. Today's performance shows a gain of 1.38%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Camlin Fine Sciences Ltd offers a dividend yield of 0.90%, which means for every ₹100 invested at the current price of ₹102.96, you can expect to receive approximately ₹0.90 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Camlin Fine Sciences Ltd's key financial metrics include: P/E Ratio: 0.00, P/B Ratio: N/A, ROE: -1.69%, ROCE: 11.00%, Dividend Yield: 0.90%, EPS: ₹-1.58, Book Value: ₹47.98, Debt-to-Equity: 0.76, and Current Ratio: N/A. The company's market cap stands at ₹2,851.6 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Camlin Fine Sciences Ltd stock opened at ₹101 and is currently trading at ₹102.96, showing a gain of ₹1.40 (1.38%). The intraday high is ₹103.79 and low is ₹97.39. The trading volume stands at 6,70,358 shares, indicating moderate market participation today.
Camlin Fine Sciences Ltd has a Price-to-Earnings (P/E) ratio of 0.00, which means investors are willing to pay ₹0.00 for every ₹1 of earnings. With an EPS of ₹-1.58, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
Camlin Fine Sciences Ltd has a market capitalization of ₹2,851.6 crores, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹102.96) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Camlin Fine Sciences Ltd has a book value of ₹47.98 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹102.96, which is 114.6% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Camlin Fine Sciences Ltd has a Return on Equity (ROE) of -1.69% and Return on Capital Employed (ROCE) of 11.00%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
Camlin Fine Sciences Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Camlin Fine Sciences Ltd has a debt-to-equity ratio of 0.76, which measures the company's financial leverage by comparing total debt to shareholders' equity. This moderate ratio indicates balanced use of debt and equity. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Camlin Fine Sciences Ltd has an Earnings Per Share (EPS) of ₹-1.58, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹102.96 and P/E ratio of 0.00, investors are paying 0.00 times the annual earnings per share. The company may need to improve its earnings performance. Track EPS growth over quarters to assess earnings momentum.
Camlin Fine Sciences Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Camlin Fine Sciences Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Camlin Fine Sciences Ltd stock, consider: 1) Fundamental Analysis - Review P/E (0.00), ROE (-1.69%), debt-to-equity (0.76), and growth rates. 2) Technical Analysis - Check 52-week range (₹96.21 - ₹333.30), moving averages, and chart patterns. 3) Valuation - Compare current price (₹102.96) with book value (₹47.98) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Camlin Fine Sciences Ltd share is ₹1.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹102.96 is 10196x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Camlin Fine Sciences Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹96.21 - ₹333.30). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.76 indicates leverage. 4) Liquidity Risk - Based on trading volume of 6,70,358 shares. 5) Valuation Risk - P/E of 0.00 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Camlin Fine Sciences Ltd operates in the industry with key metrics: P/E ratio of 0.00, ROE of -1.69%, market cap of ₹2,851.6 crores, and dividend yield of 0.90%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.76), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Camlin Fine Sciences Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹102.96, with a 52-week range of ₹96.21 to ₹333.30. Based on fundamentals like P/E (0.00), ROE (-1.69%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Camlin Fine Sciences Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹102.96. 2) Fundamental Deterioration - Declining ROE (currently -1.69%), increasing debt (D/E: 0.76), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Camlin Fine Sciences Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.90%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.
Menu